[1]孙华,李祖隆,洪晓华,等.miRNA调控NSCLC血管生成及中医药干预机制的研究进展[J].西部中医药,2026,39(03):141-147.[doi:10.12174/j.issn.2096-9600.2026.03.26]
　SUN Hua,LI Zulong,HONG Xiaohua,et al.Research Progress on the Regulation of Angiogenesis by miRNA in NSCLC and the Intervention Mechanisms of Traditional Chinese Medicine[J].Western Journal of Traditional Chinese Medicine,2026,39(03):141-147.[doi:10.12174/j.issn.2096-9600.2026.03.26]
点击复制

miRNA调控NSCLC血管生成及中医药干预机制的研究进展()

《西部中医药》[ISSN:2096-9600/CN:62-1204/R]

卷:
39
期数:
2026年03期
页码:
141-147
栏目:
研究进展
出版日期:
2026-03-15

文章信息/Info

Title:
Research Progress on the Regulation of Angiogenesis by miRNA in NSCLC and the Intervention Mechanisms of Traditional Chinese Medicine
作者:
孙华1, 李祖隆1, 洪晓华1, 邓科汇1, 覃艳春1, 蒋锐沅1, 荣震2
1.广西中医药大学研究生院，广西 南宁 530200
2.深圳市中西医结合医院，广东 深圳 518000
Author(s):
SUN Hua1, LI Zulong1, HONG Xiaohua1, DENG Kehui1, QIN Yanchun1, JIANG Ruiyuan1, RONG Zhen2
1.Graduate School of Guangxi University of Chinese Medicine, Nanning 530001, China
2.Shenzhen Hospital of Integrated Traditional Chinese and Western Medicine, Shenzhen 518000, China
关键词:
非小细胞肺癌; 微核糖核酸; 血管生成; 中医药
Keywords:
NSCLC; miRNA; angiogenesis; TCM
分类号:
R237
DOI:
10.12174/j.issn.2096-9600.2026.03.26
文献标志码:
A
摘要:
从Folkman教授提出的肿瘤血管生成假说出发，结合微小核糖核酸（MicroRNA，miRNA）调控非小细胞肺癌（non-small cell lung cancer，NSCLC）血管生成的分子机制，探讨中医药干预NSCLC血管生成的研究进展。研究认为：1）NSCLC血管生成依赖于miRNA的调控作用，miRNA可通过靶向调控非编码RNA参与该过程，从而实现对NSCLC血管生成的精细调控；2）miR-543、miR-942、miR-128等miRNA对NSCLC血管生成具有促进或抑制作用，在NSCLC的检测、诊断、治疗、预后等方面具备应用前景；3）中医药可通过调节关键miRNA表达影响血管生成，为NSCLC血管生成干预提供低毒、高效的潜在治疗策略。
Abstract:
Building upon Professor Folkman’s tumor angiogenesis hypothesis, this paper discusses research progress on Traditional Chinese Medicine (TCM) interventions in NSCLC angiogenesis, incorporating the molecular mechanisms involving miRNA regulation. Studies suggest that: 1) angiogenesis in NSCLC is regulated by miRNAs, miRNAs can participate in the process by targeting non-coding RNAs, thus achieving fine-tuned control of NSCLC angiogenesis; 2) miRNAs including miR-543, miR-942 and miR-128 can promote or inhibit NSCLC angiogenesis, demonstrating significant potential in NSCLC detection, diagnosis, treatment, and prognosis; 3) TCM can modulate key miRNA expression to influence angiogenesis, offering a promising therapeutic strategy with low toxicity and high efficacy for NSCLC angiogenesis intervention.

相似文献/References:

[1]宋春燕,王翠英.参芎葡萄糖联合放疗治疗局部晚期非小细胞肺癌50例临床观察[J].西部中医药,2013,26(01):89.
　SONG Chunyan,WANG Cuiying.Clinical Observation on ShenXiong Glucose Combined with Radiotherapy for 50 Cases of Local Non-small-cell Lung Cancer at Advanced Stage[J].Western Journal of Traditional Chinese Medicine,2013,26(03):89.
[2]席彩霞,杨国泉,苏安平,等.贞芪益气胶囊联合 GP 方案治疗晚期非小细胞肺癌的临床研究[J].西部中医药,2014,27(09):4.
[3]廖绛阳,张红△.血府逐瘀汤加味配合γ-刀治疗气虚血瘀证中晚期非小细胞肺癌30例[J].西部中医药,2015,28(10):98.
[4]魏海东,王晓平,万毅新,等.康艾注射液联合NP方案治疗非小细胞肺癌50例疗效观察[J].西部中医药,2012,25(09):57.
　WEI Hai-dong,WANG Xiao-ping,WAN Yi-xin,et al.Kang′ai Injection and NP Therapy in the Treatment for 50 Cases of Non-Small-Cell Lung Cancer[J].Western Journal of Traditional Chinese Medicine,2012,25(03):57.
[5]郭继龙,李斌,李亚玲,等.益气养阴汤联合化疗治疗气阴两虚型中晚期非小细胞肺癌30例[J].西部中医药,2017,30(08):84.
　GUO Jilong,LI Bin,LI Yaling,et al.Qi-tonifying Yin-nourishing Decoction Combined with Chemotherapy in Treating 30 Cases of Advanced Non Small-cell Lung Cancer of Dual Deficiency Pattern of Qi-Yin[J].Western Journal of Traditional Chinese Medicine,2017,30(03):84.
[6]陈雨,周天,庞皓玥,等.基于数据挖掘分析胡凯文教授治疗非小细胞肺癌用药规律[J].西部中医药,2026,39(07):60.[doi:10.12174/j.issn.2096-9600.2026.07.14]
　CHEN Yu,ZHOU Tian,PANG Haoyue,et al.Analysis of Professor Hu Kaiwen?s Medication Patterns in the Treatment of Non-Small Cell Lung Cancer Based on Data Mining[J].Western Journal of Traditional Chinese Medicine,2026,39(03):60.[doi:10.12174/j.issn.2096-9600.2026.07.14]
[7]朱小英.舒适化护理在非小细胞肺癌化疗患者中的应用效果评价[J].西部中医药,2019,32(08):133.
　ZHU Xiaoying.Effects Evaluation of Comfortable Nursing Applied to NSCLC Patients Undergoing Chemotherapy[J].Western Journal of Traditional Chinese Medicine,2019,32(03):133.
[8]沈倩芸,李和根.中西医结合治疗570例晚期非小细胞肺癌回顾性生存分析及队列研究[J].西部中医药,2025,38(11):134.[doi:10.12174/j.issn.2096-9600.2025.11.24]
　SHEN Qianyun,LI Hegen.Retrospective Survival Analysis and Cohort Studies on 570 Cases of Advanced NSCLC Treated with Integrative Traditional Chinese and Western Medicine[J].Western Journal of Traditional Chinese Medicine,2025,38(03):134.[doi:10.12174/j.issn.2096-9600.2025.11.24]
[9]田琳,毕胜男,陈梦竹,等.基于网络药理学探索血府逐瘀汤治疗非小细胞肺癌的作用机制[J].西部中医药,2022,35(01):21.[doi:10.12174/j.issn.2096-9600.2022.01.05]
　TIAN Lin,BI Shengnan,CHEN Mengzhu,et al.Research on the Mechanism of Xuefu Zhuyu Decoction in the Treatment of NSCLC Based on Network Pharmacology[J].Western Journal of Traditional Chinese Medicine,2022,35(03):21.[doi:10.12174/j.issn.2096-9600.2022.01.05]
[10]刘爽,杨阳阳,魏巍.3-PR参与式健康教育在NSCLC患者护理中的应用[J].西部中医药,2022,35(02):137.[doi:10.12174/j.issn.2096-9600.2022.02.35]
　LIU Shuang,YANG Yangyang,WEI Wei.Application of 3-PR Participatory Health Education in the Care for NSCLC Patients[J].Western Journal of Traditional Chinese Medicine,2022,35(03):137.[doi:10.12174/j.issn.2096-9600.2022.02.35]

备注/Memo

备注/Memo:
国家自然科学基金（81660774，81760850）；广西自然科学基金（2019JJA140358）。孙华（1996—），男，硕士学位，医师。研究方向：肿瘤疾病的中医药防治。
更新日期/Last Update: 2026-03-15